This webinar includes a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions. The links between preclinical research, in vivo studies, and biomarkers are explored, as well as the unique advantages of Crown Bioscience and their service offerings.
Key Topics Include:
- How our understanding of the cancer immunity cycle impacts cancer immunotherapy development
- Which new in vitro technologies provide more physiological and translatable drug responses
- Why HCI is providing deeper insights into drug responses
- What novel solutions are on the horizon to overcome the challenges of immunotherapeutic development
Resources
Presenters
Director of Immuno-Oncology
Crown Bioscience
Trained as an immunologist, Gera Goverse has used novel technologies to study the role of different environmental factors on both the local and systemic immune system to suppress their responses in inflammatory disorders and in the field of immuno-oncology.
Since joining the team at Crown Bioscience, Gera has executed the design of many successful immuno-oncology projects to help national and international customers discover the full potential of their compounds.
Gera is motivated by studying the complex mechanisms of the regulation of the immune system, exploring tumor-cell interactions and refining ways to stimulate the immune responses towards the killing of the tumor.
Vice President
Research & Innovation
Crown Bioscience
As a pharmacologist with over 15 years of experience in the CRO/biotech industry and expertise in preclinical development of oncology drugs and vaccines, Ludovic is passionate about helping customers accelerate their early-stage drug development.
Senior Vice President of In Vitro, Head of Crown Bioscience Netherlands
Crown Bioscience
Leo Price leads Crown Bioscience’s in vitro services in Europe and the US and the Crown Bioscience sites in The Netherlands, Leiden and Utrecht. He joined Crown Bioscience in 2021 from OcellO, following Crown Bioscience’s acquisition of the company. Dr Price was the founder of OcellO, a leading provider of high content screening services, using organoids and other advanced 3D cell culture models, and served as their CEO and CSO for ten years.
Production Partner
Crown Bioscience
Crown Bioscience brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, inflammation, cardiovascular, and metabolic disease. Our premier Translational Platforms help our clients accelerate their new drug development programs.
Additional Content From Crown Bioscience
Analyzing the Suppressive TME in in Vitro Based Assays
Experts describe suppressive tumor immune microenvironment compartments and patient-derived tissue technologies capable of recapitulating the TME for clinically-relevant studies.
Targeting T Cells Within the Cancer Immunity Cycle
In this webinar, speakers will discuss the role of T cell biology in cancer immunotherapy.
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
Experts provide an overview of ex vivo and in vitro methods, techniques, and model systems for research within the cancer-immunity cycle framework.
Additional Content From Scientist.com
Synthetic Peptide Growth Factors: Forging the Path Forward for Regenerative Medicine, Cell Therapy, and Cellular Agriculture
Experts discuss how synthetic growth factors work and share application examples and data using these synthetic peptides for cell therapy and regenerative medicine.
The 3D DILI Model of Success – from Biological Relevance to Industry Application
Dr. Anna Borgström and Dr. Frauke Greve present the latest advancements in hepatic safety assessment using 3D liver spheroids.
It’s Life, but Not As We Know It: How Predictive Human Organ Models Are Transforming and Reshaping the Efficiency of Drug Discovery
Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
Related Content
Colorectal Tumor Imaging
Join Jessica Freeling as she discusses several models of colorectal cancer in mice and their imaging methods.
Contrast-Enhanced Bladder Tumor Imaging
Join Massimo Alfano, PhD, as he discusses a novel platform for bladder tumor imaging.
Pancreatic Tumor and Therapy Monitoring
Join Dr. Srivalleesha Mallidi as she discusses advances in pancreatic cancer therapies using ultrasound-guided photoacoustic imaging.